Dr. Biswas is a highly experienced microbiologist who previously worked to develop phage therapeutics at Exponential Biotherapies Inc., which became the first company to complete a phase I human clinical trial. Currently as a Chief of Bacteriophage Science Division of Genomics & Bioinformatics at Biological Defense Research Directorate, NMRC, FT. Detrick, Dr. Biswas, is engaged in developing precision based phage therapy for various bacterial infections in human. Previously as a scientist at National Institute of Health, Exponential Biotherapy Inc. & Panacea Pharmaceuticals he worked on phage therapy and phage based vaccine development. He developed specific mouse models to demonstrate the effective use of bacteriophages as anti-bacterial agents against infectious Pseudomonas, Salmonella, Escherichia and multi drug resistant Enterococcus & Acinetobacter strains. He analyzed the antibacterial activities of bacteriophage which were genotypically modified to delay inactivation by the host defense system. Dr. Biswas has contributed significantly to accelerate the developments of various phage related research works at BDRD, as a Phage Division Chief of bacteriophage research group in the past years. Results from his various phage related research works, further helped to secure several funding from Congressional Directed Medical research program (CDMRP). These funding are extremely helpful for enhancing NMRC’s phage therapeutic research work and development of potential phage library to combat multidrug resistant bacteria. Dr. Biswas is also developing a phage based platform to create and manufacture vaccine in record time. He is currently collaborating with various Universities and biomedical companies to accelerate this project. Several of these rapid vaccines have been tested on animal models and has shown promising results. Additionally, he is active in research towards development of rapid diagnostics of methicillin resistant staphylococcus using bacterial viruses. Dr. Biswas has contributed heavily to rejuvenate the ongoing bacteriophage projects for military medicine and this research will help to develop better methods for preventing and treating the infectious diseases within the military and civilian population. Dr. Biswas is also an inventor on a number of patents which were licensed previously for commercial uses. His recent patent, bacteriophage composition and methods of selection of components against specific bacteria (US Patent #10357522) is also licensed to Adaptive Phage Therapeutics (APT) for commercial uses. In the past, he also obtained a patent for his innovative phage based cancer vaccine work (US Patent #9744223). This phage based cancer vaccine is currently in phase II clinical trial. Prior to Exponential Biotherapies, he worked at University of Maryland Veterinary Medicine Department where he developed rickettsia vaccine for Potomac Horse Fever (PHF). Dr. Biswas received his Master of Science and Ph.D. from University of Maryland at College Park from the Department of Veterinary Science.